Author

Anna Viola

3 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Sep 2026

Towards Precision Medicine in Inflammatory Bowel Diseases: Pharmacogenetic Predictors of Ustekinumab Effectiveness and Persistence

Background/Objectives: Inflammatory bowel diseases (IBD), including Crohn’s disease (CD) and ulcerative colitis (UC), show substantial variability in response to biologic therapies. Ustekinumab, which targets the IL-12/23 pathway, is an established treatment for moderate-to-severe IBD; however, a proportion of patients...

Ylenia Marino, M. Rottura, Claudia Ligresti et al. · Pharmaceuticals · 0 citations

Open access Sep 2026

Dual-Layer Spectral CT for Locoregional Assessment of Rectal Cancer: A Comparison with MRI in a Pilot Study

DLSCT showed high concordance with MRI for several locoregional imaging features of rectal cancer, and may provide complementary information, particularly when MRI is contraindicated or inconclusive, but these findings do not establish equivalence to MRI or diagnostic accuracy against histopathology.

S. Mazziotti, Giorgio Ascenti, Tommaso D'Angelo et al. · Diagnostics · 0 citations

Open access Sep 2026

Real-World Effectiveness and Safety of Upadacitinib in Patients With Crohn's Disease-A Multicentre Prospective Study From the Italian Group for the Study of Inflammatory Bowel Diseases (IG-IBD).

BACKGROUND AND AIMS Upadacitinib is an oral selective JAK1 inhibitor approved for moderate-to-severe Crohn's disease (CD), but real-world prospective multicentre data in advanced therapy-experienced (AT-experienced) patients are limited. The UPGRADE-CD study evaluated its effectiveness and safety. METHODS In this pro...

B. Barberio, F. D'Amico, L. Laterza et al. · Alimentary Pharmacology and... · 0 citations